View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Jun. 30, 2019
Amendment flag	false
Document Period Focus	Q2
Document Fiscal Year Focus	2019
Current fiscal year end date	--12-31
Entity central index key	0001123494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity common stock shares outstanding		38,046,001
Trading Symbol	HBIO
Entity emerging growth	false
Entity small business	true
Entity Shell Company	false

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 4,934	$ 8,173
Accounts receivable, net of allowance for doubtful accounts of $370 and $332, respectively	18,388	21,463
Inventories	25,288	25,087
Other receivables and other assets	3,883	3,109
Total current assets	52,493	57,832
Property, plant and equipment, net	5,359	5,898
Operating Lease, Right-of-Use Asset	8,846	0
Deferred income tax assets	210	211
Amortizable intangible assets, net	40,670	44,532
Goodwill	57,239	57,304
Other indefinite lived intangible assets	1,230	1,232
Other assets	191	1,604
Total Assets	166,238	168,613
Current liabilities:
Current portion, long-term debt	2,407	5,982
Current portion, operating lease liabilities	2,295	0
Accounts payable	6,041	7,359
Deferred revenue	3,532	3,820
Accrued income taxes	612	978
Accrued expenses	4,264	5,762
Other liabilities - current	1,710	1,588
Total current liabilities	20,861	25,489
Long-term debt, less current installments	52,414	54,813
Deferred income tax liabilities	2,309	2,301
Other long term liabilities	1,610	3,286
Operating lease liabilities	8,714	0
Total liabilities	85,908	85,889
Commitments and contingencies	0	0
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 45,639,892 and 45,124,309 shares issued and 37,894,385 and 37,378,802 shares outstanding, respectively	436	436
Additional paid-in-capital	227,249	226,377
Accumulated deficit	(122,506)	(119,889)
Accumulated other comprehensive loss	(14,181)	(13,532)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	80,330	82,724
Total liabilities and stockholders' equity	$ 166,238	$ 168,613

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 370	$ 332
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	45,639,892	45,124,309
Common Stock- Shares Outstanding	37,894,385	37,378,802
Treasury Stock common shares	7,745,507	7,745,507

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 29,584	$ 31,522	$ 57,786	$ 58,281
Cost of revenues	13,629	16,167	25,677	29,657
Gross profit	15,955	15,355	32,109	28,624
Sales and marketing expenses	5,770	6,309	12,076	11,955
General and administrative expenses	4,809	5,258	10,612	10,642
Research and development expenses	2,771	2,758	5,506	5,160
Amortization of intangible assets	1,436	1,412	2,866	2,515
Impairment charges	941	0	941	0
Total operating expenses	15,727	15,737	32,001	30,272
Operating loss	228	(382)	108	(1,648)
Other income (expense):
Foreign exchange	86	345	(93)	(2)
Interest expense, net	(1,376)	(1,483)	(2,781)	(2,377)
Interest income	0	0	0	0
Other expense, net	(70)	(347)	(160)	(3,085)
Other expense, net	(1,360)	(1,485)	(3,034)	(5,464)
Loss from continuing operations before income taxes	(1,132)	(1,867)	(2,926)	(7,112)
Income tax expense (benefit)	(885)	(369)	(309)	236
Loss from continuing operations	(247)	(1,498)	(2,617)	(7,348)
Discontinued operations:
Income (loss) from discontinued operations before income taxes	0	24	0	937
Income tax (benefit) expense	0	(10)	0	(883)
Income (loss) from discontinued operations	0	34	0	1,820
Net loss	$ (247)	$ (1,464)	$ (2,617)	$ (5,528)
Loss per share:
Basic earnings per common share from continuing operations	$ (0.01)	$ (0.04)	$ (70)	$ (210)
Basic earnings (loss) per common share from discontinued operations	0	0	0	0.05
Basic loss per common share	(0.01)	(0.04)	(70)	(150)
Diluted loss per common share from continuing operations	(0.01)	(0.04)	(70)	(210)
Diluted earnings (loss) per common share from discontinued operations	0	0	0	0.05
Diluted loss per common share	$ (0.01)	$ (0.04)	$ (70)	$ (150)
Weighted average common shares:
Basic	37,735,717	36,082,258	37,682,539	35,774,334
Diluted	37,735,717	36,082,258	37,682,539	35,774,334
Comprehensive loss:
Net loss	$ (247)	$ (1,464)	$ (2,617)	$ (5,528)
Foreign currency translation adjustments	(195)	(2,938)	(191)	(1,432)
Derivatives qualifying as hedges, net of tax:
(Loss) gain on derivative instruments designated and qualifying as cash flow hedges	(298)	155	(494)	(99)
Amounts reclassified from accumulated other comprehensive loss to net loss	19	70	36	45
Total comprehensive loss	$ (721)	$ (4,177)	$ (3,266)	$ (7,014)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]
Total stockholders' equity at begining of the year, Value at Dec. 31, 2017	$ 80,900	$ 419	$ 218,792	$ (116,967)	$ (10,676)	$ (10,668)
Stock option exercises	1,986	3	1,983
Stock purchase plan	(11)	0	(11)
Vesting of restricted stock units	8	8
Shares withheld for taxes	(603)	(3)	(600)
Stock compensation expense	1,746		1,746
Net income (loss)	(5,528)			(5,528)
Other Comprehensive Income (Loss)	(1,486)				(1,486)
Total stockholders' equity at year end, Value at Jun. 30, 2018	$ 77,012	$ 427	221,910	(122,495)	(12,162)	(10,668)
Beginning balance shares at Dec. 31, 2017	42,764,000	42,764,000
Stock option exercises, shares	719,000	719,000
Stock purchase plan, shares	24,907	25,000
Vesting of restricted stock units, shares	805,000	805,000
Shares withheld for taxes, shares	(211,000)	(211,000)
Ending balance shares at Jun. 30, 2018	44,102,000	44,102,000
Total stockholders' equity at begining of the year, Value at Mar. 31, 2018	$ 79,294	$ 422	220,020	(121,031)	(9,449)	(10,668)
Stock option exercises	1,169	2	1,167
Stock purchase plan	(11)		(11)
Vesting of restricted stock units	3	3
Stock compensation expense	734		734
Net income (loss)	(1,464)			(1,464)
Other Comprehensive Income (Loss)	(2,713)				(2,713)
Total stockholders' equity at year end, Value at Jun. 30, 2018	$ 77,012	$ 427	221,910	(122,495)	(12,162)	(10,668)
Beginning balance shares at Mar. 31, 2018	43,409,000	43,409,000
Stock option exercises, shares	421,000	421,000
Stock purchase plan, shares	25,000	25,000
Vesting of restricted stock units, shares	273,000	273,000
Shares withheld for taxes, shares	(26,000)	(26,000)
Ending balance shares at Jun. 30, 2018	44,102,000	44,102,000
Total stockholders' equity at begining of the year, Value at Dec. 31, 2018	$ 82,724	$ 436	226,377	(119,889)	(13,532)	(10,668)
Stock purchase plan	(89)		(89)
Vesting of restricted stock units	0		0
Shares withheld for taxes	(423)		(423)
Stock compensation expense	1,206		1,206
Net income (loss)	(2,617)			(2,617)
Other Comprehensive Income (Loss)	(649)				(649)
Total stockholders' equity at year end, Value at Jun. 30, 2019	$ 80,330	$ 436	227,249	(122,506)	(14,181)	(10,668)
Beginning balance shares at Dec. 31, 2018	45,124,000	45,124,000
Stock option exercises, shares	3,000	3,000
Stock purchase plan, shares	93,785,000	94,000
Vesting of restricted stock units, shares	554,000	554,000
Shares withheld for taxes, shares	(135,000)	(135,000)
Ending balance shares at Jun. 30, 2019	45,640,000	45,640,000
Total stockholders' equity at begining of the year, Value at Mar. 31, 2019	$ 80,349	$ 436	226,547	(122,259)	(13,707)	(10,668)
Stock purchase plan	(89)		(89)
Vesting of restricted stock units	0		0
Shares withheld for taxes	(2)		(2)
Stock compensation expense	615		615
Net income (loss)	(247)			(247)
Other Comprehensive Income (Loss)	(474)				(474)
Total stockholders' equity at year end, Value at Jun. 30, 2019	$ 80,330	$ 436	$ 227,249	$ (122,506)	$ (14,181)	$ (10,668)
Beginning balance shares at Mar. 31, 2019	45,433,000	45,433,000
Stock purchase plan, shares	94,000	94,000
Vesting of restricted stock units, shares	114,000	114,000
Shares withheld for taxes, shares	(1,000)	(1,000)
Ending balance shares at Jun. 30, 2019	45,640,000	45,640,000

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (2,617)	$ (5,528)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	1,206	1,746
Depreciation	972	1,051
Impairment charges	941	0
Gain on sale of Denville	0	(1,251)
Loss on disposal of fixed assets	0	(3)
Amortization Of Catalog Costs	10	14
Provision for allowance for doubtful accounts	368	149
Amortization of Intangible Assets	2,866	2,562
Amortization of deferred financing costs	189	458
Deferrred Income Taxes	(1)	(96)
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	2,681	(993)
(Increase) decrease in inventories	(209)	2,139
Decrease (increase) in other receivables and other assets	150	673
Increase (decrease) in trade accounts payable	(1,382)	1,798
Increase in accrued income taxes	(361)	(344)
(Decrease) increase in accrued expenses	(1,371)	(888)
(Decrease) increase in deferred revenue	(288)	2,209
(Decrease) increase in other liabilities	(487)	(1,971)
Net cash provided by operating activities	2,667	1,725
Cash flows used in investing activities:
Additions to property, plant and equipment	(423)	(634)
Additions to catalog costs	(9)	(24)
Acquisitions, net of cash acquired	0	(68,008)
Disposition, net of cash sold	1,020	15,754
Net cash used in investing activities	588	(52,912)
Cash flows provided by (used in) financing activities:
Proceeds from issuance of debt	2,300	68,500
Repayments of debt	(8,503)	(17,247)
Payments of debt issuance costs	0	(1,928)
Net proceeds from (net taxes paid for) issuance of common stock	(334)	1,380
Net cash provided by (used in) financing activities	(6,537)	50,705
Effect of exchange rate changes on cash	43	373
(Decrease) increase in cash and cash equivalents	(3,239)	(109)
Cash and cash equivalents at the begining of period	8,173	5,733
Cash and cash equivalents at the end of period	4,934	5,624
Supplemental cash flow information [Abstract]
Cash paid for interest	2,861	2,448
Cash refunded for income taxes	$ 299	$ (208)

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2018 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on March 18, 2019. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2019, results of operations and comprehensive income (loss) for the three and six months ended June 30, 2019 and 2018 and cash flows for the six months ended June 30, 2019 and 2018, as applicable, have been made. The results of operations for the three months ended June 30, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Prior Period Financial Statement Correction of Immaterial Error During the quarter ended March 31, 2019, the Company identified an immaterial misclassification error in the Company’s consolidated balance sheet as of December 31, 2018. The immaterial misclassification understated current portion, long term debt and overstated long term debt, less current installments. This misclassification, in the amount of approximately $4.0 million, related to the classification of the Company’s excess cash flow payment made to its lenders during the quarter ended March 31, 2019 as long term instead of current on its consolidated balance sheet at December 31, 2018. The misclassification had no impact on total reported debt. Refer to footnote 14 for further details. The Company assessed the materiality of this error on the financial statements for prior periods in accordance with the SEC Staff Accounting Bulletin (SAB) No. 99, Materiality, codified in Accounting Standards Codification (ASC) 250, Presentation of Financial Statements, and concluded that it was not material to any prior annual or interim periods. The Company recorded an adjustment to decrease long term debt, less current installments and increase current portion, long term debt in the consolidated balance sheet at December 31, 2018 with no impact on total reported debt. Reclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that had a major effect on the Company’s operations and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and six months ended June 30, 2018 have been presented in discontinued operations in the consolidated statements of operations. These reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive income (loss), consolidated statements of cash flows for any of the periods presented. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 18, 2019. Except for the accounting for leases as noted below there have been no material changes in the company’s significant accounting policies during the six months ended June 30, 2019. Leases The Company accounts for its leases in accordance with ASC 842 Leases. The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight line basis over the lease term. As of June 30, 2019, the Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for its leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

Recently Issued Accounting Pronouncements	6 Months Ended
Recently Issued Accounting Pronouncements	Jun. 30, 2019
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 815, Derivatives and Hedging, which updates certain guidance previously issued in ASU No. 2017-12, Derivatives and Hedging (Topic 815). The ASU is effective as of January 1, 2020, which is the beginning of the first annual period beginning after the issuance of the ASU for public entities that have adopted ASU No. 2017-12. Entities may elect either to retrospectively apply all amendments in the ASU or to prospectively apply all amendments as of the date of adoption of the ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Recently Adopted Accounting Pronouncements In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) which amends the hedge accounting recognition and presentation requirements in ASC 815, Derivatives and Hedging. The Board’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers. The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2018. The Company adopted this guidance as of January 1, 2019, and it did not have a material impact on its consolidated financial position, results of operations and cash flows. In February 2016, the FASB issued ASU No. 2016-02, Leases, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on its balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company elected to utilize a practical expedient in its method of adoption of the standard and adopted the guidance as of January 1, 2019. Under this expedient, which is a “current-period adjustment method,” the Company applied ASC 842 as of January 2019 and recognized operating lease liabilities of $11.7 million and right of use assets of $9.4 million for all leases with lease terms of more than 12 months. There was no impact to retained earnings as of that date. In addition, the Company adopted the guidance by electing the following practical expedients: (1) the Company did not reassess whether any expired or existing contracts contained leases, (2) the Company did not reassess the lease classification for any expired or existing leases, and (3) the Company excluded variable payments from the lease contract consideration and recorded those as incurred. The Company’s future commitments under lease obligations and additional disclosures are summarized in Note 12.

Accumulated Other Comprehensive Income Loss

6 Months Ended

Jun. 30, 2019

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income Disclosure [Text Block]

3. Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax are as follows:

	Foreign currency		Derivatives
	translation		qualifying as		Defined benefit
(in thousands)	adjustments		hedges		pension plans		Total
Balance at December 31, 2018	$	(12,630)	$	(170)	$	(732)	$	(13,532)
Other comprehensive income (loss) before reclassifications		(191)		(494)		-		(685)
Amounts reclassified from AOCI		-		36		-		36
Other comprehensive income (loss)		(191)		(458)		-		(649)
Balance at June 30, 2019	$	(12,821)	$	(628)	$	(732)	$	(14,181)

Acquisitions

6 Months Ended

Jun. 30, 2019

Acquisition Disclosure [Abstract]

Acquisitions Disclosure [Text Block]

4. Acquisition

On January 31, 2018, the Company acquired all of the issued and outstanding shares of Data Sciences International, Inc. (DSI), a Delaware corporation, for approximately $71.1 million. The Company funded the acquisition from its existing cash balances, excess proceeds from the Denville Transaction discussed in Note 5, and proceeds from the Financing Agreement discussed in Note 14.

DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. Its customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs and government researchers. This acquisition diversifies the Company’s customer base into the biopharmaceutical and contract research organization markets.

The aggregate purchase price for this acquisition was allocated to tangible and intangible net assets acquired as follows:

		(in thousands)
Tangible assets	$	34,010
Liabilities assumed		(11,949)
Net assets		22,061

Goodwill and intangible assets:
Goodwill		21,865
Amortizable intangible assets:
Trade name		3,524
Developed technology		25,570
Customer relationships		9,837
In-process research and development		1,387
Total amortizable intangible assets		40,318
Deferred tax liabilities, net		(13,120)
Total goodwill and intangible assets, net of tax		49,063
Acquisition purchase price	$	71,124


Tangible assets and liabilities assumed, as referenced above, consisted of the following:

Cash acquired	$	2,576
Accounts receivable, net		5,069
Inventories		11,512
Other current assets		810
Property, plant and equipment, net		3,574
Deferred income tax assets, net		10,469
Tangible assets	$	34,010

Accounts payable and accrued liabilities	$	6,001
Deferred revenue including customer advances		2,976
Other long term liabilities		2,972
Liabilities assumed	$	11,949

The Company finalized the purchase price allocation for DSI as of December 31, 2018. The weighted-average amortization periods for definite-lived intangible assets acquired was 9.4 years for tradenames, 8.2 years for developed technology, 12.4 years for customer relationships and 7.4 years for in-process research and development assets. The weighted average amortization period for all definite-lived intangible assets acquired was 9.3 years. Goodwill recorded as a result of the acquisition of DSI is not deductible for tax purposes.

The results of operations for DSI have been included in the Company’s consolidated financial statements from the date of acquisition. The revenues of DSI included in the Company’s consolidated statement of operations from the date of acquisition to June 30, 2018 were approximately $18.2 million. The net loss of DSI included in the Company’s consolidated statement of operations for the same period was approximately $1.7 million. Included in the net loss for the six months ended June 30, 2018 was a $3.7 million charge recognized in cost of revenues related to purchase accounting inventory fair value step up amortization. The total inventory fair value step up was valued at $3.8 million and was recognized into cost of revenues over one inventory turn, or approximately five and a half months. Also included in the net loss of DSI for that period was $1.8 million of intangible asset amortization expense.

The following consolidated pro forma information is based on the assumption that was used at the time of the acquisition of DSI. Accordingly, the historical results have been adjusted to reflect amortization expense, interest expense and other purchase accounting adjustments that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had the Company completed the acquisition during these periods or which might be reported in the future.


	Six Months Ended
	June 30,
	2018
	(in thousands)
Pro Forma
Revenues	$	61,671
Income (loss) from continuing operations		(392)

Direct acquisition costs recorded in other expense, net in the Company’s consolidated statements of operations were $2.6 million for the six months ended June 30, 2018.

Discontinued Operations

6 Months Ended

Jun. 30, 2019

Discontinued Operations [Abstract]

Discontinued Operations Disclosure [Text Block]

5. Discontinued Operations

On January 22, 2018, the Company sold substantially all the assets of its wholly owned subsidiary, Denville, for approximately $20.0 million, which included a $3.0 million earn-out provision (the Denville Transaction). Upon the closing of the transaction, the Company received $15.7 million. The $3.0 million earn-out provision represented consideration that was contingent on Denville achieving certain performance metrics with respect to 2018 and 2019 (

The following table is a reconciliation of the major line items of income from discontinued operations presented within the Company’s consolidated statements of operations for the three and six months ended June 30, 2018.

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2018		2018
	(in thousands)
Revenues	$	-	$	893
Cost of revenues		-		(534)
Operating and other expenses		-		(673)
Gain on disposal of discontinued operations		24		1,251
Income from discontinued operations before income taxes		24		937
Income tax benefit		(10)		(883)
Income from discontinued operations	$	34	$	1,820

During the three months ended June 30, 2019, the Company received a release of an escrow amount of $1.0 million related to the Denville Transaction, which is included in the investing cash flows for disposition in the Company’s consolidated statements of cash flows for the six months ended June 30, 2019. Total operating cash flows for Denville in the Company’s consolidated statements of cash flows for the six months ended June 30, 2018, were immaterial.

Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2019

Goodwill And Other Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets Disclosure [Text Block]

6. Goodwill and Other Intangible Assets

Intangible assets consist of the following:

									Weighted
									Average
		June 30, 2019				December 31, 2018			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	41,205	$	(18,004)	$	41,268	$	(16,215)	6.6	Years
Trade names		7,809		(3,182)		7,828		(2,861)	7.2	Years
Distribution agreements/customer relationships		22,603		(10,147)		22,657		(9,509)	10.2	Years
In-process research and development		446		(60)		1,387		(30)	6.4	Years
Patents		211		(211)		211		(204)	-	Years
Total amortizable intangible assets		72,274	$	(31,604)		73,351	$	(28,819)

Indefinite-lived intangible assets:
Goodwill		57,239				57,304
Other indefinite-lived intangible assets		1,230				1,232
Total goodwill and other indefinite-lived intangible assets		58,469				58,536

Total intangible assets, gross	$	130,743			$	131,887

(a) Weighted average life as of June 30, 2019.

The change in the carrying amount of goodwill for the six months ended June 30, 2019 is as follows:

			(in thousands)
Balance at December 31, 2018		$	57,304
	Effect of change in currency translation		(65)
Balance at June 30, 2019		$	57,239

Intangible asset amortization expense from continuing operations was $1.4 million for the three months ended June 30, 2019 and 2018, respectively. Intangible asset amortization expense from continuing operations was $2.9 million and $2.5 million for the six months ended June 30, 2019 and 2018, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $5.6 million for the year ending December 31, 2019, $5.6 million for the year ending December 31, 2020, $5.6 million for the year ending December 31, 2021, $5.5 million for the year ending December 31, 2022, $5.4 million for the year ending December 31, 2023, and $5.3 million for the year ending December 31, 2024.

During the three months ended June 30, 2019, the Company recognized an impairment charge of $0.9 million related to certain of its in-process research and development intangible assets as a result of the on-going evaluation of its capitalized research and development activities. There was no impairment charge recognized during the three and six months ended June 30, 2018.

Inventories

6 Months Ended

Jun. 30, 2019

Inventories Disclosure [Abstract]

Inventories Disclosure [Text Block]

7. Inventories

Inventories consist of the following:

			June 30,		December 31,
			2019		2018
			(in thousands)
Finished goods		$	6,729	$	6,936
Work in process			4,101		3,667
Raw materials			14,458		14,484
	Total	$	25,288	$	25,087

Property, Plant and Equipment

6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment Disclosure [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

8. Property, Plant and Equipment

As of June 30, 2019 and December 31, 2018, property, plant and equipment consist of the following:

		June 30,		December 31,
		2019		2018
		(in thousands)
Land, buildings and leasehold improvements	$	2,527	$	2,468
Machinery and equipment		9,914		9,678
Computer equipment and software		9,814		9,685
Furniture and fixtures		1,406		1,390
Automobiles		114		115
		23,775		23,336
Less: accumulated depreciation		(18,416)		(17,438)
Property, plant and equipment, net	$	5,359	$	5,898

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI) in 2014, the Company signed lease agreements with the former owners of these acquired companies. The principals of such former owners of MCS and TBSI were employees of the Company as of June 30, 2019 and 2018. Pursuant to these lease agreements, the Company made rent payments of approximately $89 thousand and $81 thousand to these former owners for the three months ended June 30, 2019 and 2018, respectively. The Company made rent payments of approximately $178 thousand and $171 thousand to these former owners for the six months ended June 30, 2019 and 2018, respectively.

Warranties

6 Months Ended

Jun. 30, 2019

Warranties Disclosure [Abstract]

Warranties Disclosure [Text Block]

10. Warranties

Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows:

		Beginning	(Payments)\			Ending
		Balance	Credits	Additions		Balance
		(in thousands)

Year ended December 31, 2018	$	246	(37)	182	$	391

Six months ended June 30, 2019	$	391	(79)	6	$	318

Employee Benefit Plans

6 Months Ended

Jun. 30, 2019

Employee Benefit Plans Disclosure [Abstract]

Employee Benefit Plans Disclosure [Text Block]

11. Employee Benefit Plans

The Company’s subsidiary in the United Kingdom, Biochrom Limited, maintains contributory, defined benefit pension plans for substantially all of its employees. These defined benefit pension plans have been closed to new employees since 2014, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows:

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2019		2018		2019		2018
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	123	$	118	$	255	$	250
Expected return on plan assets		(170)		(184)		(352)		(388)
Net amortization loss		71		52		147		110
Net periodic benefit cost (income)	$	24	$	(14)	$	50	$	(28)

For the three months ended June 30, 2019 and 2018, the Company contributed $0.2 million, for both periods, to its defined benefit pension plans. For the six months ended June 30, 2019 and 2018, the Company contributed $0.4 million and $0.4 million, respectively to its defined benefit pension plans. The Company expects to contribute approximately $0.3 million to its defined benefit pension plans during the remainder of 2019.

The Company had an underfunded pension liability of approximately $0.9 million as of June 30, 2019 and December 31, 2018 included in the other long term liabilities line item in the consolidated balance sheets.

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases [Text Block]

12. Leases

The Company has noncancelable operating leases for office, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2023 and thereafter. As discussed in Footnote 1, the Company adopted ASC 842 as of January 1, 2019, using a current period adjustment method. In accordance with this method, the Company recognized a right of use asset of $9.4 million and an operating lease liability of $11.7 million as of January 1, 2019. As a result of using the current period adjustment method, the lease expense for six months ended June 30, 2019 and 2018 was recognized under ASC 842, and ASC 840, the previous standard, respectively.

The components of lease expense for the three and six months ended June 30, 2019 are as follows:

		Three Months Ended			Six Months Ended
		June 30, 2019			June 30, 2019
		(in thousands)			(in thousands)
Operating lease cost	$	515		$	1,038
Short term lease cost		51			127
Sublease income		(103)			(205)
Total lease cost	$	463		$	960

Supplemental cash flow information related to the Company's operating leases was as follows

		Six Months Ended
		June 30, 2019
		(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	1,367

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	-

Supplemental balance sheet information related to the Company's operating leases was as follows:

		June 30, 2019
		(in thousands)
Operating lease right-of use assets	$	8,846

Current portion, operating lease liabilities	$	2,295
Operating lease liabilities, long term		8,714
Total operating lease liabilities	$	11,009

Weighted average remaining lease term		8.5	years
Weighted average discount rate		9.2%

Rent payments for continuing operations were approximately $1.4 million for the six months ended June 30, 2018. Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at June 30, 2019, are as follows:

	Operating
	Leases
	(in thousands)
2020	$	2,295
2021		2,108
2022		1,852
2023		1,804
2024		1,798
Thereafter		6,543
Total lease payments		16,400
Less interest		(5,391)
Total operating lease liabilities	$	11,009

Capital Stock

6 Months Ended

Jun. 30, 2019

Capital Stock Disclosure [Abstract]

Capital Stock Disclosure [Text Block]

13. Capital Stock

Common Stock

The Company has 80.0 million shares of common stock authorized for issuance. As of June 30, 2019, the Company had 37.9 million shares of common stock issued and outstanding.

Preferred Stock

The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price, privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of June 30, 2019, the Company had no preferred stock issued or outstanding.

Employee Stock Purchase Plan (as amended, the ESPP)

In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employees can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. As of June 30, 2019, 1,400,000 shares of common stock are authorized for issuance, of which 984,547 shares were issued. There were 93,785 and 24,907 shares issued under the ESPP during the six months ended June 30, 2019 and 2018, respectively.

Stock Option and Equity Incentive Plans

Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the Third A&R Plan)

The Third Amendment to the Third A&R Plan (the Amendment) was adopted by the Board of Directors on April 2, 2018. Such Amendment was approved by the stockholders at the Company’s 2018 Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 3,400,000 shares to 20,908,929.

Restricted Stock Units with a Market Condition (the Market Condition RSUs)

On May 24, 2018, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2018 Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan. The vesting of the 2018 Market Condition RSUs is based on a graded-vesting schedule (one third at the end of each year for three years) and linked to the achievement of a relative total shareholder return of the Company’s common stock from May 24, 2018 to the earlier of (i) May 24, 2019 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). As of June 30, 2019, the target number of these restricted stock units that may be earned is 7,556 shares; the maximum amount is 150% of the target number.

On March 7, 2019, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2019 Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan. The vesting of the 2019 Market Condition RSUs is based on a graded-vesting schedule (one third at the end of each year for three years) and linked to the achievement of a relative total shareholder return of the Company’s common stock from March 7, 2019 to the earlier of (i) March 7, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). As of June 30, 2019, the target number of these restricted stock units that may be earned is 56,517 shares; the maximum amount is 150% of the target number.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, Market Condition RSUs and employee stock purchases related to the ESPP. The Company has elected as an accounting policy to account for forfeitures for service based awards as they occur, with no adjustment for estimated forfeitures.

Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the six months ended June 30, 2019 was as follows:

		Stock Options			Restricted Stock Units			Market Condition RSU's
			Weighted
		Stock	Average		Restricted			Market
		Options	Exercise		Stock Units	Grant Date		Condition RSU's	Grant Date
		Outstanding	Price		Outstanding	Fair Value		Outstanding	Fair Value

Balance at December 31, 2018		1,956,732	$	4.25	1,233,762	$	3.36	116,944	$	4.19
	Granted	587,909		3.73	599,977		3.19	75,514		4.16
	Exercised	(2,500)		3.25	-		-	-		-
	Expired	(2,635)		2.28	-		-	-		-
	Vested (RSUs)	-		-	(550,200)		3.46	(3,778)		4.19
	Cancelled / forfeited	(356,649)		4.03	(229,883)		3.48	(124,607)		4.19
Balance at June 30, 2019		2,182,857	$	4.15	1,053,656	$	3.19	64,073	$	4.16

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Volatility	47.76	%	42.31	%	45.69	%	42.31	%
Risk-free interest rate	1.86	%	2.82	%	2.42	%	2.82	%
Expected holding period (in years)	4.70	years	4.95	years	4.73	years	4.95	years
Dividend yield	-	%	-	%	-	%	-	%

	Six Months Ended
	June 30,
	2019		2018
Volatility	48.00	%	44.02	%
Risk-free interest rate	2.50	%	2.27	%
Correlation coefficient	0.27	%	0.07	%
Dividend yield	-	%	-	%

The Company used historical volatility to calculate the expected volatility for each grant as of the grant date. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options and Market Condition RSUs. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. The correlation coefficient, used to value the Market Condition RSUs, represents the way in which entities move in relation to the NASDAQ Biotechnology index as a whole.

Stock-based compensation expense related to stock options, restricted stock units, Market Condition RSUs and the ESPP for the three and six months ended June 30, 2019 and 2018 was allocated as follows:

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2019		2018		2019		2018
		(in thousands)

Cost of revenues	$	8	$	15	$	21	$	26
Sales and marketing		36		102		29		226
General and administrative		529		576		1,080		1,273
Research and development		42		41		76		71
Discontinued operations		-		-		-		150
Total stock-based compensation	$	615	$	734	$	1,206	$	1,746

The Company did not capitalize any stock-based compensation.

Earnings per share

Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018

Basic	37,735,717	36,082,258	37,682,539	35,774,334
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs	-	-	-	-
Diluted	37,735,717	36,082,258	37,682,539	35,774,334

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSUs of approximately 3,300,586 and 4,737,057 shares of common stock for the six months ended June 30, 2019 and 2018, respectively, as the impact of these shares would be anti-dilutive.

Long Term Debt

6 Months Ended

Jun. 30, 2019

Long Term Debt Disclosure [Abstract]

Long Term Debt Disclosure [Text Block]

14. Long Term Debt

On January 22, 2018, in connection with the closing of the Denville Transaction, the Company terminated the Third Amended and Restated Credit Agreement (the Credit Agreement), among the Company, Brown Brothers Harriman & Co. and each of the other lenders party thereto, and Bank of America, as administrative agent. All outstanding amounts under the agreement were repaid in full using a portion of the proceeds of the Denville Transaction. At the time of repayment, there was approximately $11.9 million outstanding.

On January 31, 2018, the Company entered into a financing agreement by and among the Company and certain subsidiaries of the Company parties thereto, as borrowers (collectively, the Borrower), certain subsidiaries of the Company parties thereto, as guarantors, various lenders from time to time party thereto (the Lenders), and Cerberus Business Finance, LLC, as collateral agent and administrative agent for the Lenders (the Financing Agreement). On August 16, 2018, the Company and Cerberus Business Finance, LLC entered into a First Amendment to the Financing Agreement, which such amendment modified certain provisions related to the borrowing base and reporting, among other things.

The Financing Agreement provided for senior secured credit facilities (the Senior Secured Credit Facilities) comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. The proceeds of the term loan and $4.8 million of advances under the revolving line of credit were used to fund a portion of the DSI acquisition, and to pay fees and expenses related thereto and the closing of the Senior Secured Credit Facilities. In addition, the revolving facility is available for use by the Company and its subsidiaries for general corporate and working capital needs, and other purposes to the extent permitted by the Financing Agreement. The Senior Secured Credit Facilities have a maturity of five years.

Commencing on March 31, 2018, the outstanding term loans began to amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity. Furthermore, within ten days of the Company’s delivery of its audited annual financial statements each year, the term loans are permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep” of 50% of the consolidated excess cash flow; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. During the three months ended March 31, 2019, the Company made an excess cash flow payment of $4.0 million as required by the Financing Agreement. Additionally, during the three months ended June 30, 2019, the Company made a payment, as required by the Financing Agreement, of $1.0 million in connection with the release of an escrow amount associated with the Denville Transaction discussed in Note 5.

The obligations of the Borrower under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and certain of the Company’s existing and subsequently acquired or organized subsidiaries. The Senior Secured Credit Facilities and related guarantees are secured on a first-priority basis (subject to certain liens permitted under the Financing Agreement) by a lien on substantially all the tangible and intangible assets of the Borrower and the subsidiary guarantors, including all of the capital stock held by such obligors (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions.

Interest on all loans under the Senior Secured Credit Facilities is paid monthly. Borrowings under the Financing Agreement accrue interest at a per annum rate equal to, at the Borrower’s option, a base rate plus 4.75% or a London Interbank Offered Rate (LIBOR) rate plus 6.25%. The loans are also subject to a 1.25% interest rate floor for LIBOR loans and a 4.25% interest rate floor for base rate loans.

The Financing Agreement contains customary representations and warranties and affirmative covenants applicable to the Company and its subsidiaries and also contains certain restrictive covenants, including, among others, limitations on the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of the Company’s capital stock, prepayments of certain debt, transactions with affiliates and modifications of organizational documents, material contracts, affiliated practice agreements and certain debt agreements. The Financing Agreement also contains customary events of default. As of June 30, 2019, the Company was in compliance with all financial covenants contained in the Financing Agreement, was subject to covenant and working capital borrowing restrictions and had available borrowing capacity under its Financing Agreement of $9.5 million.

As of June 30, 2019, the weighted effective interest rate, net of the impact of the Company’s interest rate swap, on its term loan was 8.85%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As of June 30, 2019 and December 31, 2018, the Company’s borrowings were comprised of:

		June 30,		December 31,
		2019		2018
		(in thousands)
Long-term debt:
Term loan	$	56,197	$	62,400
Total unamortized deferred financing costs		(1,376)		(1,605)
Total debt		54,821		60,795
Less: current installments		(2,800)		(6,383)
Current unamortized deferred financing costs		393		401
Long-term debt	$	52,414	$	54,813

Derivatives

6 Months Ended

Jun. 30, 2019

Derivatives [Abstract]

Derivatives Disclosure [Text Block]

15. Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows.

The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged.

As disclosed in Note 14, on January 31, 2018, the Company entered into a Financing Agreement comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. Shortly after entering into the Financing Agreement, the Company entered into an interest rate swap contract with PNC Bank with a notional amount of $36.0 million and a termination date of January 1, 2023 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. The swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with a portion of the term loan under the Financing Agreement at 2.72%. The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC 815 “Derivatives and Hedging”.

The following table presents the notional amount and fair value of the Company’s derivative instruments as of June 30, 2019 and December 31, 2018

			June 30, 2019
			Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	31,591	$	(628)


			December 31, 2018
			Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	34,090	$	(170)

	(a) See Note 16 for the fair value measurements related to these financial instruments.

All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (AOCI). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three and six months ended June 30, 2019 and 2018:

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three months ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
	(in thousands)
Interest rate swaps	$	(298)	$	155	$	(494)	$	(99)

The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three and six months ended June 30, 2019 and 2018:

Details about AOCI Components			Amount reclassified from AOCI into income (effective portion)
	Three Months Ended					Six Months Ended				Location of amount reclassified from AOCI
	June 30,					June 30,				Location of amount reclassified from AOCI
	2019			2018		2019		2018		into income (effective portion)
	(in thousands)
Interest rate swaps	$	19		$	70	$	36	$	45	Interest expense

As of June 30, 2019, $0.2 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable-rate debt.

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

The weighted average fair value of the options granted under the Third A&R Plan during the three months ended June 30, 2019 and 2018 was $0.97 and $1.81, respectively, and during the six months ended June 30, 2019 and 2018 was $1.56 and $1.81, respectively. The following assumptions were used to estimate the fair value, using the Black-Scholes option pricing model, of stock options granted during the three and six months ended June 30, 2019:

The weighted average fair value of the 2019 Market Condition RSUs which were granted under the Third A&R Plan during the three months ended March 31, 2019 was $4.16. There were no Market Condition RSUs granted under the Third A&R Plan during the three months ended June 30, 2019. The weighted average fair value of the 2018 Market Condition RSUs which were granted under the Third A&R Plan during the three months ended June 30, 2018 was $4.19. There were no Market Condition RSUs granted under the Third A&R Plan during the three months ended March 31, 2018. The following assumptions were used to estimate the fair value, using a Monte-Carlo valuation simulation, of the Market Condition RSUs granted during the six months ended June 30, 2019 and 2018:

16. Fair Value Measurements

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s own assumptions.

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

	Fair Value as of June 30, 2019
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(628)	$	-	$	(628)


	Fair Value as of December 31, 2018
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(170)	$	-	$	(170)

The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Revenues

6 Months Ended

Jun. 30, 2019

Revenues Disclosure [Abstract]

Revenues

17. Revenues

The following table represents a disaggregation of revenue from contracts with customers. Revenue from continuing operations originating from the following geographic areas for the six months ended June 30, 2019 and 2018 consist of:

	Three Months Ended June 30, 2019
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	20,920	$	2,399	$	3,271	$	1,753	$	28,343
Service, maintenance and warranty contracts		910		236		79		16		1,241
Total revenues	$	21,830	$	2,635	$	3,350	$	1,769	$	29,584


	Three Months Ended June 30, 2018
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	20,478	$	4,058	$	3,316	$	2,156	$	30,008
Service, maintenance and warranty contracts		1,204		168		129		13		1,514
Total revenues	$	21,682	$	4,226	$	3,445	$	2,169	$	31,522


	Six Months Ended June 30, 2019
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	39,591	$	5,528	$	6,184	$	3,798	$	55,101
Service, maintenance and warranty contracts		2,053		426		176		30		2,685
Total revenues	$	41,644	$	5,954	$	6,360	$	3,828	$	57,786


	Six Months Ended June 30, 2018
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	36,695	$	7,587	$	7,006	$	4,400	$	55,688
Service, maintenance and warranty contracts		2,030		334		198		31		2,593
Total revenues	$	38,725	$	7,921	$	7,204	$	4,431	$	58,281

Deferred revenue

As of June 30, 2019 and December 31, 2018, the Company had approximately $3.5 million and $3.8 million, respectively, in deferred revenue comprised of revenue deferred from service contracts and revenue deferred from advance payments.

Changes in deferred revenue from service contracts and advance payments from customers during the six months ended June 30, 2019 and 2018 were as follows:

	Three Months Ended June 30, 2019
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at March 31, 2019	$	1,666	$	2,049	$	3,715
Deferral of revenue		281		140		421
Recognition of deferred revenue		(344)		(250)		(594)
Effect of foreign currency translation		(10)		-		(10)
Balance at June 30, 2019	$	1,593	$	1,939	$	3,532


	Three Months Ended June 30, 2018
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at March 31, 2018	$	1,793	$	2,060	$	3,853
Addition due to business combination		(1)		-		(1)
Deferral of revenue		1,090		116		1,206
Recognition of deferred revenue		(1,169)		(323)		(1,492)
Effect of foreign currency translation		(19)		-		(19)
Balance at June 30, 2018	$	1,694	$	1,853	$	3,547


	Six Months Ended June 30, 2019
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at December 31, 2018	$	1,659	$	2,161	$	3,820
Deferral of revenue		1,126		251		1,377
Recognition of deferred revenue		(1,192)		(473)		(1,665)
Effect of foreign currency translation		-		-		-
Balance at June 30, 2019	$	1,593	$	1,939	$	3,532


	Six Months Ended June 30, 2018
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at December 31, 2017	$	505	$	-	$	505
Addition due to business combination		848		2,128		2,976
Deferral of revenue		2,283		244		2,527
Recognition of deferred revenue		(1,927)		(519)		(2,446)
Effect of foreign currency translation		(15)		-		(15)
Balance at June 30, 2018	$	1,694	$	1,853	$	3,547

Allowance for doubtful accounts

Activity in the allowance for doubtful accounts was as follows:

	Six Months Ended June 30,
		2019		2018
		(in thousands)

Balance, beginning of period	$	332	$	193
Addition due to business combination		-		102
Bad debt expense		368		149
Charge-offs and other recoveries		(329)		-
Effect of foreign currency translation		(1)		77
Balance, end of period	$	370	$	521

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2019
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	18. Income Tax Income tax benefit from continuing operations was approximately $0.9 million and $0.4 million for the three months ended June 30, 2019 and 2018, respectively. The effective tax rate on continuing operations was 78.2% for the three months ended June 30, 2019 compared with 19.8% for the same period in 2018. Income tax from continuing operations was a benefit of approximately $0.3 million and an expense of $0.2 million for the six months ended June 30, 2019 and 2018, respectively. The effective tax rate on continuing operations was 10.6% for the six months ended June 30, 2019, compared with (3.3%) for the same period in 2018. The difference between the Company’s effective tax rates in 2019 and 2018 compared to the U.S. statutory tax rate of 21% is primarily due to the mix of year-to-date and forecasted income or losses in the U.S. and foreign tax jurisdictions, the impact of different tax rates in certain foreign jurisdictions, the impact of the inclusion of foreign income in U.S. taxable income under the GILTI (Global Intangible Low-Taxed Income) tax rules, limitations on interest expense deductions and, in 2018, certain non-deductible acquisition costs. For the three and six months ended June 30, 2019, no income tax expense or benefit was recorded for discontinued operations. For the comparable three-and six-month periods in 2018, income tax benefit recorded for discontinued operations was $10 thousand and $0.9 million.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation Policies [Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2018 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on March 18, 2019. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2019, results of operations and comprehensive income (loss) for the three and six months ended June 30, 2019 and 2018 and cash flows for the six months ended June 30, 2019 and 2018, as applicable, have been made. The results of operations for the three months ended June 30, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Reclassifications [Policy Text Block]	Reclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that had a major effect on the Company’s operations and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and six months ended June 30, 2018 have been presented in discontinued operations in the consolidated statements of operations. These reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive income (loss), consolidated statements of cash flows for any of the periods presented.
Leases [Policy Text Block]	Leases The Company accounts for its leases in accordance with ASC 842 Leases. The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right to the Company to control the use of identified property, plant or equipment for period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight line basis over the lease term. As of June 30, 2019, the Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately. Additionally, for its leases, the Company applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

Accumulated Other Comprehensive Income (Tables)

6 Months Ended

Jun. 30, 2019

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income [Table Text Block]

	Foreign currency		Derivatives
	translation		qualifying as		Defined benefit
(in thousands)	adjustments		hedges		pension plans		Total
Balance at December 31, 2018	$	(12,630)	$	(170)	$	(732)	$	(13,532)
Other comprehensive income (loss) before reclassifications		(191)		(494)		-		(685)
Amounts reclassified from AOCI		-		36		-		36
Other comprehensive income (loss)		(191)		(458)		-		(649)
Balance at June 30, 2019	$	(12,821)	$	(628)	$	(732)	$	(14,181)

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2019

Acquisition Disclosure [Abstract]

Schedule of Business Acquisitions [Table Text Block]

		(in thousands)
Tangible assets	$	34,010
Liabilities assumed		(11,949)
Net assets		22,061

Goodwill and intangible assets:
Goodwill		21,865
Amortizable intangible assets:
Trade name		3,524
Developed technology		25,570
Customer relationships		9,837
In-process research and development		1,387
Total amortizable intangible assets		40,318
Deferred tax liabilities, net		(13,120)
Total goodwill and intangible assets, net of tax		49,063
Acquisition purchase price	$	71,124


Tangible assets and liabilities assumed, as referenced above, consisted of the following:

Cash acquired	$	2,576
Accounts receivable, net		5,069
Inventories		11,512
Other current assets		810
Property, plant and equipment, net		3,574
Deferred income tax assets, net		10,469
Tangible assets	$	34,010

Accounts payable and accrued liabilities	$	6,001
Deferred revenue including customer advances		2,976
Other long term liabilities		2,972
Liabilities assumed	$	11,949

Business Acquisition, Pro Forma Information [Table Text Block]


	Six Months Ended
	June 30,
	2018
	(in thousands)
Pro Forma
Revenues	$	61,671
Income (loss) from continuing operations		(392)

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2019

Discontinued Operations [Abstract]

Disposal Groups, Including Discontinued Operations,Income Loss [Table Text Blcok]

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2018		2018
	(in thousands)
Revenues	$	-	$	893
Cost of revenues		-		(534)
Operating and other expenses		-		(673)
Gain on disposal of discontinued operations		24		1,251
Income from discontinued operations before income taxes		24		937
Income tax benefit		(10)		(883)
Income from discontinued operations	$	34	$	1,820

Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2019

Goodwill And Other Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

									Weighted
									Average
		June 30, 2019				December 31, 2018			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	41,205	$	(18,004)	$	41,268	$	(16,215)	6.6	Years
Trade names		7,809		(3,182)		7,828		(2,861)	7.2	Years
Distribution agreements/customer relationships		22,603		(10,147)		22,657		(9,509)	10.2	Years
In-process research and development		446		(60)		1,387		(30)	6.4	Years
Patents		211		(211)		211		(204)	-	Years
Total amortizable intangible assets		72,274	$	(31,604)		73,351	$	(28,819)

Indefinite-lived intangible assets:
Goodwill		57,239				57,304
Other indefinite-lived intangible assets		1,230				1,232
Total goodwill and other indefinite-lived intangible assets		58,469				58,536

Total intangible assets, gross	$	130,743			$	131,887

(a) Weighted average life as of June 30, 2019.

Goodwill Rollforward [Table Text Block]

			(in thousands)
Balance at December 31, 2018		$	57,304
	Effect of change in currency translation		(65)
Balance at June 30, 2019		$	57,239

Inventories (Tables)

6 Months Ended

Jun. 30, 2019

Inventories Disclosure [Abstract]

Schedule of Inventory [Table Text Block]

			June 30,		December 31,
			2019		2018
			(in thousands)
Finished goods		$	6,729	$	6,936
Work in process			4,101		3,667
Raw materials			14,458		14,484
	Total	$	25,288	$	25,087

Property, Plant and Equipment (Tables)

6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment Disclosure [Abstract]

Schedule Of Property Plant And Equipment [Table Text Block]

		June 30,		December 31,
		2019		2018
		(in thousands)
Land, buildings and leasehold improvements	$	2,527	$	2,468
Machinery and equipment		9,914		9,678
Computer equipment and software		9,814		9,685
Furniture and fixtures		1,406		1,390
Automobiles		114		115
		23,775		23,336
Less: accumulated depreciation		(18,416)		(17,438)
Property, plant and equipment, net	$	5,359	$	5,898

Warranties (Tables)

6 Months Ended

Jun. 30, 2019

Warranties Disclosure [Abstract]

Warranty Rollforward Disclosure [Table Text Block]

		Beginning	(Payments)\			Ending
		Balance	Credits	Additions		Balance
		(in thousands)

Year ended December 31, 2018	$	246	(37)	182	$	391

Six months ended June 30, 2019	$	391	(79)	6	$	318

Employee Benefit Plans (Tables)

6 Months Ended

Jun. 30, 2019

Employee Benefit Plans Disclosure [Abstract]

Schedule of Changes in Projected Benefit Obligations [Table Text Block]

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2019		2018		2019		2018
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	123	$	118	$	255	$	250
Expected return on plan assets		(170)		(184)		(352)		(388)
Net amortization loss		71		52		147		110
Net periodic benefit cost (income)	$	24	$	(14)	$	50	$	(28)

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Lessee, Operating Lease, Disclosure [Table Text Block]

		Three Months Ended			Six Months Ended
		June 30, 2019			June 30, 2019
		(in thousands)			(in thousands)
Operating lease cost	$	515		$	1,038
Short term lease cost		51			127
Sublease income		(103)			(205)
Total lease cost	$	463		$	960

Supplemental cash flow information related to the Company's operating leases was as follows

		Six Months Ended
		June 30, 2019
		(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	1,367

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	-

Supplemental balance sheet information related to the Company's operating leases was as follows:

		June 30, 2019
		(in thousands)
Operating lease right-of use assets	$	8,846

Current portion, operating lease liabilities	$	2,295
Operating lease liabilities, long term		8,714
Total operating lease liabilities	$	11,009

Weighted average remaining lease term		8.5	years
Weighted average discount rate		9.2%

Future minimum lease payments for operating leases [Table Text Block]

	Operating
	Leases
	(in thousands)
2020	$	2,295
2021		2,108
2022		1,852
2023		1,804
2024		1,798
Thereafter		6,543
Total lease payments		16,400
Less interest		(5,391)
Total operating lease liabilities	$	11,009

Capital Stock (Tables)

6 Months Ended

Jun. 30, 2019

Capital Stock Disclosure [Abstract]

Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]

		Stock Options			Restricted Stock Units			Market Condition RSU's
			Weighted
		Stock	Average		Restricted			Market
		Options	Exercise		Stock Units	Grant Date		Condition RSU's	Grant Date
		Outstanding	Price		Outstanding	Fair Value		Outstanding	Fair Value

Balance at December 31, 2018		1,956,732	$	4.25	1,233,762	$	3.36	116,944	$	4.19
	Granted	587,909		3.73	599,977		3.19	75,514		4.16
	Exercised	(2,500)		3.25	-		-	-		-
	Expired	(2,635)		2.28	-		-	-		-
	Vested (RSUs)	-		-	(550,200)		3.46	(3,778)		4.19
	Cancelled / forfeited	(356,649)		4.03	(229,883)		3.48	(124,607)		4.19
Balance at June 30, 2019		2,182,857	$	4.15	1,053,656	$	3.19	64,073	$	4.16

Stock Based Compensation Expense Activity By Function [Table Text Block]

		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2019		2018		2019		2018
		(in thousands)

Cost of revenues	$	8	$	15	$	21	$	26
Sales and marketing		36		102		29		226
General and administrative		529		576		1,080		1,273
Research and development		42		41		76		71
Discontinued operations		-		-		-		150
Total stock-based compensation	$	615	$	734	$	1,206	$	1,746

Basic and Diluted Shares [Table Text Block]

	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018

Basic	37,735,717	36,082,258	37,682,539	35,774,334
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs	-	-	-	-
Diluted	37,735,717	36,082,258	37,682,539	35,774,334

Black-Scholes option pricing model [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]

Table Of Assumptions [Table Text Block]

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Volatility	47.76	%	42.31	%	45.69	%	42.31	%
Risk-free interest rate	1.86	%	2.82	%	2.42	%	2.82	%
Expected holding period (in years)	4.70	years	4.95	years	4.73	years	4.95	years
Dividend yield	-	%	-	%	-	%	-	%

Monte-Carlo valuation simulation [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]

Table Of Assumptions [Table Text Block]

	Six Months Ended
	June 30,
	2019		2018
Volatility	48.00	%	44.02	%
Risk-free interest rate	2.50	%	2.27	%
Correlation coefficient	0.27	%	0.07	%
Dividend yield	-	%	-	%

Long Term Debt (Tables)

6 Months Ended

Jun. 30, 2019

Long Term Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

		June 30,		December 31,
		2019		2018
		(in thousands)
Long-term debt:
Term loan	$	56,197	$	62,400
Total unamortized deferred financing costs		(1,376)		(1,605)
Total debt		54,821		60,795
Less: current installments		(2,800)		(6,383)
Current unamortized deferred financing costs		393		401
Long-term debt	$	52,414	$	54,813

Derivative (Tables)

6 Months Ended

Jun. 30, 2019

Derivatives [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

			June 30, 2019
			Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	31,591	$	(628)


			December 31, 2018
			Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	34,090	$	(170)

	(a) See Note 16 for the fair value measurements related to these financial instruments.

Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three months ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
	(in thousands)
Interest rate swaps	$	(298)	$	155	$	(494)	$	(99)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components			Amount reclassified from AOCI into income (effective portion)
	Three Months Ended					Six Months Ended				Location of amount reclassified from AOCI
	June 30,					June 30,				Location of amount reclassified from AOCI
	2019			2018		2019		2018		into income (effective portion)
	(in thousands)
Interest rate swaps	$	19		$	70	$	36	$	45	Interest expense

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]

	Fair Value as of June 30, 2019
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(628)	$	-	$	(628)


	Fair Value as of December 31, 2018
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	(170)	$	-	$	(170)

Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Revenues Disclosure [Abstract]

Disaggregation of Revenue [Table Text Block]

	Three Months Ended June 30, 2019
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	20,920	$	2,399	$	3,271	$	1,753	$	28,343
Service, maintenance and warranty contracts		910		236		79		16		1,241
Total revenues	$	21,830	$	2,635	$	3,350	$	1,769	$	29,584


	Three Months Ended June 30, 2018
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment, software and accessories	$	20,478	$	4,058	$	3,316	$	2,156	$	30,008
Service, maintenance and warranty contracts		1,204		168		129		13		1,514
Total revenues	$	21,682	$	4,226	$	3,445	$	2,169	$	31,522


	Six Months Ended June 30, 2019
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	39,591	$	5,528	$	6,184	$	3,798	$	55,101
Service, maintenance and warranty contracts		2,053		426		176		30		2,685
Total revenues	$	41,644	$	5,954	$	6,360	$	3,828	$	57,786


	Six Months Ended June 30, 2018
		(in thousands)
	United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	36,695	$	7,587	$	7,006	$	4,400	$	55,688
Service, maintenance and warranty contracts		2,030		334		198		31		2,593
Total revenues	$	38,725	$	7,921	$	7,204	$	4,431	$	58,281

Activity in allowance for doubtful accounts [Table Text Block]

	Six Months Ended June 30,
		2019		2018
		(in thousands)

Balance, beginning of period	$	332	$	193
Addition due to business combination		-		102
Bad debt expense		368		149
Charge-offs and other recoveries		(329)		-
Effect of foreign currency translation		(1)		77
Balance, end of period	$	370	$	521

Service Contracts [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

	Three Months Ended June 30, 2019
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at March 31, 2019	$	1,666	$	2,049	$	3,715
Deferral of revenue		281		140		421
Recognition of deferred revenue		(344)		(250)		(594)
Effect of foreign currency translation		(10)		-		(10)
Balance at June 30, 2019	$	1,593	$	1,939	$	3,532


	Three Months Ended June 30, 2018
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at March 31, 2018	$	1,793	$	2,060	$	3,853
Addition due to business combination		(1)		-		(1)
Deferral of revenue		1,090		116		1,206
Recognition of deferred revenue		(1,169)		(323)		(1,492)
Effect of foreign currency translation		(19)		-		(19)
Balance at June 30, 2018	$	1,694	$	1,853	$	3,547


	Six Months Ended June 30, 2019
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at December 31, 2018	$	1,659	$	2,161	$	3,820
Deferral of revenue		1,126		251		1,377
Recognition of deferred revenue		(1,192)		(473)		(1,665)
Effect of foreign currency translation		-		-		-
Balance at June 30, 2019	$	1,593	$	1,939	$	3,532


	Six Months Ended June 30, 2018
	(in thousands)
	Service Contracts		Customer Advances		Total
Balance at December 31, 2017	$	505	$	-	$	505
Addition due to business combination		848		2,128		2,976
Deferral of revenue		2,283		244		2,527
Recognition of deferred revenue		(1,927)		(519)		(2,446)
Effect of foreign currency translation		(15)		-		(15)
Balance at June 30, 2018	$	1,694	$	1,853	$	3,547

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Summary of Significant Accounting Policies [Abstract]
Immaterial Error Correction	The immaterial misclassification understated current portion, long term debt and overstated long term debt, less current installments. This misclassification, in the amount of approximately $4.0 million, related to the classification of the Company’s excess cash flow payment made to its lenders during the quarter ended March 31, 2019 as long term instead of current on its consolidated balance sheet at December 31, 2018. The misclassification had no impact on total reported debt.
Classification of the Company's excess cash flow payment [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Miscalculation amount		$ 4

Recently Issued Accounting Pronouncements (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 8,846	$ 9,400	$ 0
Operating lease liabilities	$ 11,009	$ 11,700

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			$ (13,532)
Other Comprehensive Income (Loss) before Reclassifications			(685)
Amounts reclassified from AOCI			36
Other Comprehensive Income (Loss), Net of Tax, total	$ (474)	$ (2,713)	(649)	$ (1,486)
Closing Balance	(14,181)		(14,181)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(12,630)
Other Comprehensive Income (Loss) before Reclassifications			(191)
Amounts reclassified from AOCI			0
Other Comprehensive Income (Loss), Net of Tax, total			(191)
Closing Balance	(12,821)		(12,821)
Derivatives qualifying as hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(170)
Other Comprehensive Income (Loss) before Reclassifications			(494)
Amounts reclassified from AOCI			36
Other Comprehensive Income (Loss), Net of Tax, total			(458)
Closing Balance	(628)		(628)
Defined benefit pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance			(732)
Other Comprehensive Income (Loss) before Reclassifications			0
Amounts reclassified from AOCI			0
Other Comprehensive Income (Loss), Net of Tax, total			0
Closing Balance	$ (732)		$ (732)

Acquisitions (Narratives) (Details) - USD ($) $ in Millions		3 Months Ended	5 Months Ended	6 Months Ended
Acquisitions (Narratives) (Details) - USD ($) $ in Millions	Jan. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition		Jan. 31, 2018
Acquisition purchase price	$ 71.1
Business Acquisition, Description of Acquired Entity				DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers.
Business Acquisition Direct Acquisition Costs In Income Statement			$ 2.6
The results of operations for DSI:
Revenue of Acquiree since Acquisition Date			18.2
Earnings or Loss of Acquiree since Acquisition Date			1.7
Busniess combination purchase accounting inventory fair value step up amortization			3.7
Preliminary amount of inventory fair value step up			3.8
Intangible asset amortization expense			$ 1.8
Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 3 months 18 days
Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 2 months 12 days
Trade Names [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 4 months 24 days
Developed Technology [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				6 years 7 months 6 days
Developed Technology [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				8 years 2 months 12 days
Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				10 years 2 months 12 days
Customer Relationships [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				12 years 4 months 24 days
In-process research and development [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				6 years 4 months 24 days
In-process research and development [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 4 months 24 days

Acquisitions (Details) - USD ($) $ in Thousands	6 Months Ended
Acquisitions (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Jan. 31, 2018
Goodwill and intangible assets
Goodwill		$ 57,239	$ 57,304
Data Sciences International, Inc. (DSI) [Member]
Recognized Identifiable Assets Acquired and Liabilities Assumed [Abstract]
Tangible assets				$ 34,010
Liabilities assumed				(11,949)
Net assets				22,061
Goodwill and intangible assets
Goodwill				21,865
Amortizable intangible assets				40,318
Deferred tax, net				(13,120)
Total goodwill and intangible assets, net of tax				49,063
Acquisition purchase price				71,124
Tangible assets and liabilities assumed, as referenced above, preliminarily consist of the following:
Cash acquired				2,576
Accounts receivable, net				5,069
Inventories				11,512
Other current assets				810
Property, plant and equipment, net				3,574
Deferred income tax assets, net				10,469
Tangible assets				34,010
Accounts payable and accrued liabilities				6,001
Deferred revenue including customer advances				2,976
Other long term liabilities				2,972
Liabilities assumed				11,949
Business Acquisitions Pro Forma Revenue	$ 61,671
Business Acquisitions Pro Forma Net Income Loss	$ (392)
Trade Names [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				3,524
Developed Technology [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				25,570
Customer Relationships [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				9,837
In-process research and development [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets				$ 1,387

Discontinued Operations (Narrative) (Details) - USD ($)		3 Months Ended	6 Months Ended
Discontinued Operations (Narrative) (Details) - USD ($)	Jan. 22, 2018	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Discontinued Operations [Abstract]
Discontinued Operation, Name	Denville
Sale price of of assets Denville	$ 20,000,000
Earn out provision of discontinued operations	3,000,000
Proceeds From Divestiture Of Business			$ 1,020,000	$ 15,754,000
Contingent Consideration, Earn-out	3,000,000
Potential consideration year 2018	2,000,000
Potential consideration year 2019	$ 1,000,000
Earnout earned, year 2018		$ 0
Contingent consideration earnout maximum		$ 1,000,000	1,000,000
Earn out performance metrics period	2 years
Proceeds from divestiture of DSI			$ 1,020,000	$ 15,754,000

Discontinued Operations - income (loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Discontinued Operation, Income Statement Disclosures [Abstract]
Revenues		$ 0		$ 893
Cost of revenues		0		(534)
Operating and other expenses		0		(673)
Gain on disposal of discontinued operations		24		1,251
Income (loss) from discontinued operations before income taxes	$ 0	24	$ 0	937
Income tax (benefit) expense	0	(10)	0	(883)
Income (loss) from discontinued operations	$ 0	$ 34	$ 0	$ 1,820

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,436	$ 1,412	$ 2,866	$ 2,515
Impairment charges	941	$ 0	941	$ 0
Remaining year ending December 31, 2019	5,600		5,600
Year ending December 31, 2020	5,600		5,600
Year ending December 31, 2021	5,600		5,600
Year ending December 31, 2022	5,500		5,500
Year ending December 31, 2023	5,400		5,400
Year ending December 31, 2024	$ 5,300		$ 5,300

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 72,274	$ 73,351
Finite-Lived Intangible Assets, Accumulated Amortization	(31,604)	(28,819)
Goodwill	57,239	57,304
Other indefinite lived intangible assets	1,230	1,232
Total goodwill and other indefinite lived intangible assets	58,469	58,536
Total intangible assets	130,743	131,887
Existing technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	41,205	41,268
Finite-Lived Intangible Assets, Accumulated Amortization	$ (18,004)	(16,215)
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 7 months 6 days
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,809	7,828
Finite-Lived Intangible Assets, Accumulated Amortization	$ (3,182)	(2,861)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 2 months 12 days
Distribution agreements/customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 22,603	22,657
Finite-Lived Intangible Assets, Accumulated Amortization	$ (10,147)	(9,509)
Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years 2 months 12 days
In-process research and development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 446	1,387
Finite-Lived Intangible Assets, Accumulated Amortization	$ (60)	(30)
Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years 4 months 24 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 211	211
Finite-Lived Intangible Assets, Accumulated Amortization	$ (211)	$ (204)

Goodwill and Other Intangible Assets - Change in carrying amount of goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 57,304
Effect of change in currency translation	(65)
Goodwill, Ending Balance	$ 57,239

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventories Disclosure [Abstract]
Finished Goods	$ 6,729	$ 6,936
Work in Process	4,101	3,667
Raw Materials	14,458	14,484
Total Inventories, Net	$ 25,288	$ 25,087

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 23,775	$ 23,336
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(18,416)	(17,438)
Property, plant and equipment, net	5,359	5,898
Land, buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,527	2,468
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,914	9,678
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,814	9,685
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,406	1,390
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 114	$ 115

Related Party Transactions (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net				$ 1,400
MCS GmbH (MCS) and Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 89	$ 81	$ 178	$ 171

Warranties (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
Warranties (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 391	$ 246
Warranty (payments) or credits	(79)	(37)
Warranty additions	6	182
Warranty, Ending Balance	$ 318	$ 391

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year	$ 0.3		$ 0.3
Defined Benefit Plan Payments In Current Fiscal Year	0.2	$ 0.2	0.4	$ 0.4
Defined Benefit Plans Liabilities Noncurrent	$ 0.9		$ 0.9		$ 0.9

Employee Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Employee Benefit Plans (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Benefit Plans Disclosure [Abstract]
Interest Cost	$ 123	$ 118	$ 255	$ 250
Expected Return on Plan Assets	(170)	(184)	(352)	(388)
Net Amortization Loss	71	52	147	110
Net Periodic Benefit Cost, Total	$ 24	$ (14)	$ 50	$ (28)

Leases (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Leases (Narratives) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Lease Expiration Date	Dec. 31, 2023
Operating Lease, Right-of-Use Asset	$ 8,846		$ 9,400	$ 0
Operating lease liabilities	$ 11,009		$ 11,700
Operating Leases, Rent Expense, Net		$ 1,400

Leases - Components of lease expense and other supplementary information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Components of lease expense:
Operating lease cost	$ 515	$ 1,038
Short term lease cost	51	127
Sublease income	(103)	(205)
Total lease cost	463	960
Supplemental cash flow information [Abstract]
Operating cash flows from operating leases	1,367
Right-of-use assets obtained in exchange for lease obligations, operating leases	0
Supplemental balance sheet information [Abstract]
Operating lease right-of use assets	8,846	8,846	$ 9,400	$ 0
Current portion, operating lease liabilities	2,295	2,295		0
Operating lease liabilities, long term	8,714	8,714		$ 0
Operating lease liabilities	$ 11,009	$ 11,009	$ 11,700
Weighted average remaining lease term	8 years 6 months	8 years 6 months
Weighted average discount rate	9.20%	9.20%

Leases - Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 2,295
2021	2,108
2022	1,852
2023	1,804
2024	1,798
Thereafter	6,543
Total lease payments	16,400
Less interest	(5,391)
Total operating lease liabilities	$ 11,009	$ 11,700

Capital Stock (Narratives) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Apr. 02, 2018
Common stock
Common Stock- Shares Authorized	80,000,000			80,000,000		80,000,000
Common Stock- Shares Issued	45,639,892			45,639,892		45,124,309
Common Stock- Shares Outstanding	37,894,385			37,894,385		37,378,802
Preferred Stock
Preferred stock issued or outstanding	0			0
Preferred Stock - Shares Authorized	5,000,000			5,000,000		5,000,000
Employee Stock Purchase Plan (as amended, the ESPP)
Total amount of common stock issued under ESOP	984,547			984,547
Employee Stock Purchase Plan Shares Authorized	1,400,000			1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Stock issued during the year, Shares, Employee Stock Purchase Plans	94,000		25,000	93,785,000	24,907
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							20,908,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan							3,400,000
Target number of these restricted stock units				599,977
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	10 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				3,300,586	4,737,057
Weighted Average Estimated Black Scholes Value Of Option Grants	$ 0.97		$ 1.81	$ 1.56	$ 1.81
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 0		$ 3	$ 0	$ 8
Maximum percentage of target number of restricted stock units	150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value				$ 3.73
Stock options, Granted				587,909
Market Condition Restricted Stock Unit [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				75,514
2018 Market Condition RSUs [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				7,556
Maximum percentage of target number of restricted stock units				150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value					$ 4.19
2019 Market Condition RSUs [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Target number of these restricted stock units				56,517
Maximum percentage of target number of restricted stock units				150.00%
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value		$ 4.16
Minimum [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Maximum [Member]
Employee Stock Purchase Plan (as amended, the ESPP)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years

Capital Stock - Stock options and restricted stock activity (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Opening Balance Stock Options Outstanding		1,956,732
Stock options, Granted		587,909
Stock option, Exercised	(421,000)	(3,000)	(719,000)
Expired		(2,635)
Stock options, Cancelled and Forfeited		(356,649)
Closing Balance Stock Options Outstanding		2,182,857
Begining Balance Weighted Average Exercise Price		$ 4.25
Stock Options, Weighted Average Exercise Price, Granted		3.73
Stock Options, Weighted Average Exercise Price, Exercised		3.25
Stock Options, Weighted Average Exercise Price, Expired		2.28
Stock Options, Weighted Average Exercise Price, Cancelled / Forfeited		4.03
Closing Balance Weighted Average Exercise Price		$ 4.15
Begining Balance Restricted Stock Units Outstanding		1,233,762
Restricted stock units, Granted		599,977
Retricted Stock Units, Vested		(550,200)
Restricted Stock Units, Cancelled/ Forfeited		(229,883)
Closing Balance Restricted Stock Units Outstanding		1,053,656
Begining Balance Grant Date Fair Value Of Restricted Stock Units		$ 3.36
Restricted Stock Units Grant Date Fair Value, Granted		3.19
Restricted Stock Unit, Grant Date Fair Value, Vested		3.46
Restricted Stock Unit Grant Date Fair Value, Forfeited		3.48
Closing Balance Grant Date Fair Value Of Restricted Stock Units		$ 3.19
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Begining Balance Restricted Stock Units Outstanding		116,944
Restricted stock units, Granted		75,514
Retricted Stock Units, Vested		(3,778)
Restricted Stock Units, Cancelled/ Forfeited		(124,607)
Closing Balance Restricted Stock Units Outstanding		64,073
Begining Balance Grant Date Fair Value Of Restricted Stock Units		$ 4.19
Restricted Stock Units Grant Date Fair Value, Granted		4.16
Restricted Stock Unit, Grant Date Fair Value, Vested		4.19
Restricted Stock Unit Grant Date Fair Value, Forfeited		4.19
Closing Balance Grant Date Fair Value Of Restricted Stock Units		$ 4.16

Capital Stock - Assumptions Black Scholes and Monte Carlo (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Black-Scholes option pricing model [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	47.76%	42.31%	45.69%	42.31%
Risk-free interest rate	1.86%	2.82%	2.42%	2.82%
Expected holding period (in years)	4 years 8 months 12 days	4 years 11 months 12 days	4 years 8 months 23 days	4 years 11 months 12 days
Dividend yield	0.00%	0.00%	0.00%	0.00%
Monte-Carlo valuation simulation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	0.00%		48.00%	44.02%
Risk-free interest rate	0.00%		2.50%	2.27%
Correlation coefficient	0.00%		0.27%	0.07%
Dividend yield	0.00%		0.00%	0.00%

Capital Stock - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 615	$ 734	$ 1,206	$ 1,746
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	8	15	21	26
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	36	102	29	226
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	529	576	1,080	1,273
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	42	41	76	71
Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 0	$ 0	$ 0	$ 150

Capital Stock - Weighted average number of shares (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	37,735,717	36,082,258	37,682,539	35,774,334
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSU's	0	0	0	0
Diluted	37,735,717	36,082,258	37,682,539	35,774,334

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Jan. 31, 2018	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Jan. 22, 2018
Debt Instrument [Line Items]
Secured Debt		$ 54,821		$ 54,821	$ 60,795
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Maturity of debt instrument in years and months				5 years
Debt Instrument, Payment Terms	the outstanding term loans began to amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.
Debt Instrument Quarterly Payment Current Year						$ 400
Debt Instrument Quarterly Payment Next Year						600
Debt Instrument Quarterly Payment Thereafter						$ 800
Limitation on pledges of capital stock of foreign subsidiaries		65.00%		65.00%
Line of Credit Facility, Amount Outstanding							$ 11,900
Line of Credit Facility, Remaining Borrowing Capacity		$ 9,500		$ 9,500
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Line of Credit Facility, Amount Outstanding	$ 4,800
Revolving Credit Facility [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	a base rate plus 4.75%
Basis Spread on Variable Rate	4.75%
Floor Interest Rate	4.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	London Interbank Offered Rate (LIBOR) rate plus 6.25%
Basis Spread on Variable Rate	6.25%
Floor Interest Rate	1.25%
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	$ 64,000
Percentage of excess cash flow		50.00%		50.00%
Prepayment of senior debt		$ 1,000
Interest Rate As Of Reporting Date		8.85%		8.85%
Excess cash flow [Member]
Debt Instrument [Line Items]
Prepayment of senior debt			$ 4,000
Denville Transaction [Member]
Debt Instrument [Line Items]
Prepayment of senior debt		$ 1,000

Long Term Debt - Borrowings (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument
Term Loan	$ 56,197	$ 62,400
Total unamortized deferred financing costs	(1,376)	(1,605)
Total Debt	54,821	60,795
Less: current installments	(2,800)	(6,383)
Current unamortized deferred financing costs	393	401
Long-term debt	$ 52,414	$ 54,813

Derivative (Narratives) (Details) - USD ($)		3 Months Ended	6 Months Ended
Derivative (Narratives) (Details) - USD ($)	Jan. 31, 2018	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings		$ 93,000	$ 200,000
Derivative Interest Rate Swap Effective Percentage		100.00%
Secured Debt		$ 54,821,000	54,821,000	$ 60,795,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Other liabilities-non current [Member] \| Derivatives qualifying as hedges [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Derivatives		$ 31,591,000	$ 31,591,000	$ 34,090,000
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps	$ 36,000,000
LIBOR Fixed Rate	2.72%
Secured Debt	$ 64,000,000

Derivative (Details) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 31,591	$ 34,090
Derivative Liability, Fair Value, Net	$ (628)	$ (170)

Derivative - Other comprehensive income loss (Details) - Derivatives qualifying as hedges [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ (298,000)	$ 155,000	$ (494,000)	$ (99,000)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ 19,000	$ 70,000	$ 36,000	$ 45,000

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ (628)	$ (170)
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	(628)	(170)
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Revenues - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 29,584	$ 31,522	$ 57,786	$ 58,281
Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	28,343	30,008	55,101	55,688
Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,241	1,514	2,685	2,593
Segment, Geographical, United States [Member]
Disaggregation of Revenue [Line Items]
Revenues	21,830	21,682	41,644	38,725
Segment, Geographical, United States [Member] \| Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	20,920	20,478	39,591	36,695
Segment, Geographical, United States [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	910	1,204	2,053	2,030
Segment, Geographical, United Kingdom [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,635	4,226	5,954	7,921
Segment, Geographical, United Kingdom [Member] \| Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,399	4,058	5,528	7,587
Segment, Geographical, United Kingdom [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	236	168	426	334
Segment, Geographical, Germany [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,350	3,445	6,360	7,204
Segment, Geographical, Germany [Member] \| Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,271	3,316	6,184	7,006
Segment, Geographical, Germany [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	79	129	176	198
Rest Of The World [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,769	2,169	3,828	4,431
Rest Of The World [Member] \| Instruments, equipment software and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,753	2,156	3,798	4,400
Rest Of The World [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 16	$ 13	$ 30	$ 31

Revenues - Deferred revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	$ 3,715	$ 3,853	$ 3,820	$ 505
Addition due to business combination		(1)		2,976
Deferral of revenue	421	1,206	1,377	2,527
Recognition of deferred revenue	(594)	(1,492)	(1,665)	(2,446)
Effect of foreign currency translation	(10)	(19)	0	(15)
Deferred Revenue, ending balance	3,532	3,547	3,532	3,547
Service Contracts [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	1,666	1,793	1,659	505
Addition due to business combination		(1)		848
Deferral of revenue	281	1,090	1,126	2,283
Recognition of deferred revenue	(344)	(1,169)	(1,192)	(1,927)
Effect of foreign currency translation	(10)	(19)	0	(15)
Deferred Revenue, ending balance	1,593	1,694	1,593	1,694
Customer Advances [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	2,049	2,060	2,161	0
Addition due to business combination		0		2,128
Deferral of revenue	140	116	251	244
Recognition of deferred revenue	(250)	(323)	(473)	(519)
Effect of foreign currency translation	0	0	0	0
Deferred Revenue, ending balance	$ 1,939	$ 1,853	$ 1,939	$ 1,853

Revenues - Allowance for doubtful debts (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
AllowanceForDoubtfulAccountsReceivableRollforward
Balance, beginning of period	$ 332	$ 193
Addition due to business combination	0	102
Bad debt expense	368	149
Bad debt (recoveries)	(329)	0
Effect of foreign currency translation adjustment	(1)	77
Balance, end of period	$ 370	$ 521

Income Tax (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Tax (Narratives) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax [Abstract]
Effective Income Tax Rate	78.20%	19.80%	10.60%	(3.30%)
Income tax expense (benefit)	$ (885)	$ (369)	$ (309)	$ 236
Discontinued Operation, Tax Effect of Discontinued Operation	$ 0	$ (10)	$ 0	$ (883)
US Federal Income Tax Rate, based on Tax Cuts And Jobs Act Of 2017			21.00%

- Definition

+ References + Details